What this study is
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
What's being tested
- Qudexy XR
Intervention · DRUG
Extended-Release Capsule
- Placebo
Intervention · DRUG
Qudexy XR Matching capsules
Study details
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age
- Sponsor
- Upsher-Smith Laboratories
- Conditions
- Migraine Disorders
- Enrolling
- 132 people
- Starts
- 2021-02-19
- Est. completion
- 2026-09
- Design
- Quadruple-blind, randomized, parallel groups, Phase 4
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 6 Years – 11 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)
- Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on 95 percentile weight for the age range.11
- Subject has at least a 6-month history of headaches consistent with a diagnosis of migraine with or without aura (International Classification of Headache Disorders, 3rd Edition [ICHD 3]).
- Subject had ≥8 self-reported headache days in the 28 days prior to Screening.
- Subject has a PedMIDAS score >10, indicating at least mild disruption in daily activities, and <140, indicating extreme disability that may require more comprehensive, multi component therapy.
You can't join if
- Subject has continuous migraines, defined as an unrelenting headache for a 28-day period.
- Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3 months prior to Visit 1 (Screening).
- Subject is currently receiving migraine prevention medication and has initiated or changed the dose within 28 days of Screening or is unwilling to avoid making a change during the duration of the study.
- Subject has previously failed an adequate trial of topiramate (at least 3 months duration at a clinically appropriate dose) for prophylaxis of migraine headache due to lack of efficacy or AEs.
- Subject has previously failed an adequate trial of >3 migraine preventative medications.
- Subject has a known history of allergic reaction to topiramate or any excipient in Qudexy XR.
- Subject has a diagnosis or history of disease that may interfere with safety or evaluation of the study drug.
- Subject is currently using an investigational drug or device or has used such within 30 days prior to Visit 1.
- Subject has begun menses and any of the following:; Subject has tested positive for pregnancy; OR; Subject is pregnant, planning pregnancy, or lactating; OR; Subject is taking an oral hormonal contraceptive (either combined [estrogen and progestogen containing] or progestogen-only) and is unable or unwilling to switch to an alternative highly effective contraceptive method.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (15)
6 openUpsher-Smith Clinical Trial Site #15
La Jolla, California, United States
RecruitingUpsher-Smith Clinical Trial Site #14
Tampa, Florida, United States
RecruitingUpsher-Smith Clinical Trial Site #4
Cincinnati, Ohio, United States
RecruitingUpsher-Smith Clinical Trial Site #6
Portland, Oregon, United States
RecruitingUpsher-Smith Clinical Trials Site #7
Springfield, Oregon, United States
RecruitingUpsher-Smith Clinical Trial Site #9
Huntington, West Virginia, United States
RecruitingUpsher-Smith Clinical Trial Site #5
Birmingham, Alabama, United States
WithdrawnUpsher-Smith Clinical Trials Site #3
Aurora, Colorado, United States
WithdrawnUpsher-Smith Clinical Trial Site #1
Stamford, Connecticut, United States
CompletedUpsher-Smith Clinical Trial Site #12
Loxahatchee Groves, Florida, United States
WithdrawnUpsher-Smith Clinical Trial Site #8
Orlando, Florida, United States
WithdrawnUpsher-Smith Clinical Trial Site #2
Ann Arbor, Michigan, United States
WithdrawnUpsher-Smith Clinical Trial Site #11
Jackson, Mississippi, United States
WithdrawnUpsher-Smith Clinical Trial Site #10
Bridgeton, Missouri, United States
WithdrawnUpsher-Smith Clinical Trial Site #13
McAllen, Texas, United States
Withdrawn
Study team
Sponsor
Upsher-Smith Laboratories
Study ID P255-501
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.